Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage III Esophageal Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Conditions
Keywords
Creatine, Cur-cumin, Early Cachexia
Brief summary
Cachexia is a common complication of various advanced malignant tumors, which seriously affects the quality of life and survival time of patients. In view of the clinical problem of non-nutritional response in patients with cachexia, the investigators plan to carry out a clinical case-control study on the intervention of creatine combined with curcumin in participants with cachexia. On the whole, the investigators limited the study subjects to upper digestive tract tumors and diagnosed participants with early cachexia. The main purpose of this study is to determine whether the combination of the two can play a positive and stable role in inhibiting the inflammation of cachexia and improving metabolic status, so that basic nutrition can play a role, in order to reduce the level of skeletal muscle consumption, maintain weight, improve quality of life, save medical costs and extend survival time.
Detailed description
This is a prospective open controlled study. The intervention is targeted at participants with early cachexia in upper gastrointestinal tumors.Both control group and intervention group receive basic nutritional support. On the basis of this, the intervention group will be given creatine and curcumin orally.The purpose is to investigate whether creatine combined with curcumin can improve the inflammatory and the nutritional state, correct the disorder of nutrient metabolism and improve the prognosis of participants.
Interventions
DIETARY_SUPPLEMENTbasic nutrition
An adequate supply of energy and protein in diet, oral nutrition supplement or tube feeding enteral nutrition supplement when diet is deficient.
DIETARY_SUPPLEMENToral supplement of creatine and curcumin
Creatine and curcumin are orally added other than basic nutrition treatment.
Sponsors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of advanced tumors of the upper digestive tract with untreatable or postoperative recurrence of esophageal and gastric cancer III-IV * Meet the diagnostic criteria of early cachexia (anorexia and metabolic changes, involuntary body mass reduction ≤5% within 6 months) * Radiotherapy, chemotherapy or immunotherapy in our hospital * Understand and fill in a variety of rating scales * Informed consent, voluntary participation in this study
Exclusion criteria
* Neoadjuvant chemotherapy patients * Intestinal obstruction or gastrointestinal bleeding * Severe heart, lung and renal insufficiency * Coagulopathy * Clinical diagnosis with diabetes and other metabolic diseases * The expected survival time is less than 1 month * With cognitive dysfunction or poor coordination * Allergy to creatine or curcumin * With a history of drug abuse * Doctors or researchers deem unsuitable for study participation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| L3 skeletal muscle index(c㎡/㎡) | 0-month | CT scans L3 cross-sectional skeletal muscle area/height² |
| Appendicular skeletal muscle mass index(kg/㎡) | 0-month | Appendicular skeletal muscle mass(ASM)is measured by bioelectrical impedance analysis(BIA), the ASM index (ASM/height²)is calculated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Body Mass Index(kg/㎡) | 0-month | body weight/height² |
| Nutrition intake level(%) | 0-month | Investigate the ratio of actual energy and protein intake levels to target intake levels |
| Pre-albumin concentration(mg/L) | 0-month | Serological pre-albumin concentration |
| Functional Assessment of Anorexia/Cachexia Therapy(FAACT) | 0-month | Anorexia/Cachexia Sub-scale-12：score 0～24，Anorexia/Cachexia |
| Survival rate(%) | 1-month | (Number of surviving cases after 1 month of follow-up)/(number of cases at the beginning of follow-up) ×100% |
| PG-SGA score | 0-month | Scored Patient-Generated Subjective Global Assessment(PG-SGA)：(0-1，stage A；2-8，stage B；≥9，stageC) |
| Albumin concentration(g/L) | 0-month | Serological albumin concentration |
Contacts
Primary ContactXiaotian Chen
Outcome results
None listed